Genfit SA

GENFIT to Acquire Clinical-stage Biopharmaceutical Company Versantis, expanding its Portfolio in Liver Diseases

19 Sep 2022 00:30:00 By Nasdaq GlobeNewswire

FDA Grants GENFIT’s GNS561 Orphan Drug Designation for the Treatment of Cholangiocarcinoma

13 Sep 2022 15:10:00 By Nasdaq GlobeNewswire

GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

08 Jul 2022 15:10:00 By Nasdaq GlobeNewswire

GENFIT: May 25, 2022 Combined Shareholders Meeting results

25 May 2022 15:10:00 By Nasdaq GlobeNewswire

GENFIT Reports First Quarter 2022 Financial Information (Unaudited financial information under IFRS)

11 May 2022 15:10:00 By Nasdaq GlobeNewswire

GENFIT Announces Publication of the 2021 Universal Registration Document; the 2021 Annual Report on Form 20-F and Availability of Preparatory Documents for the Annual Combined Shareholders Meeting on May 25, 2022

29 Apr 2022 15:10:00 By Nasdaq GlobeNewswire

GENFIT Annual Combined General Meeting of May 25, 2022 — Availability of Preparatory Documents

20 Apr 2022 15:10:00 By Nasdaq GlobeNewswire

GENFIT Reports Full-Year 2021 Financial Results and Provides Corporate Update

07 Apr 2022 15:10:00 By Nasdaq GlobeNewswire

GENFIT Announces Solid Revenues and Cash Position as of December 31, 2021

28 Feb 2022 15:10:00 By Nasdaq GlobeNewswire

GENFIT: 2022 Financial Calendar

24 Jan 2022 15:10:00 By Nasdaq GlobeNewswire

GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

21 Jan 2022 15:10:00 By Nasdaq GlobeNewswire

On heels of global strategic partnership announced today, GENFIT acquires rights to novel asset

17 Dec 2021 00:15:00 By Nasdaq GlobeNewswire

GENFIT: FNIH NIMBLE Study Demonstrates NIS4® Technology’s Unique Performance in Identifying Patients with “at-risk” NASH

18 Nov 2021 15:15:00 By Nasdaq GlobeNewswire

GENFIT Announces First Patient First Visit for the Evaluation of NTZ in Subjects with Hepatic Impairment as part of its ACLF Program

09 Nov 2021 15:10:00 By Nasdaq GlobeNewswire

GENFIT: Third Quarter 2021 Financial Information

08 Nov 2021 15:10:00 By Nasdaq GlobeNewswire

New Clinical Data on GENFIT’s Investigational Compound Elafibranor to be Presented at AASLD The Liver Meeting®

02 Nov 2021 16:10:00 By Nasdaq GlobeNewswire

GENFIT Reports First Half-Year 2021 Financial Results and Provides Corporate Update

29 Sep 2021 15:10:00 By Nasdaq GlobeNewswire

GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

09 Jul 2021 15:10:00 By Nasdaq GlobeNewswire

GENFIT: June 30, 2021 Annual Shareholders Meeting results

30 Jun 2021 15:10:00 By Nasdaq GlobeNewswire

GENFIT obtains non-dilutive financing of €11 million in the form of a State Guaranteed Loan

24 Jun 2021 15:10:00 By Nasdaq GlobeNewswire